absorption of this drug from the small intestine in P-gp knockout mice. In pregnant GF120918treated P-gp-deficient mice, the relative fetal concentration of topotecan was 2-fold higher than that in pregnant vehicle-treated mice. These observations suggest that Bcrp1 (the murine ortholog of BCRP) mediates apically directed drug transport, reduces drug bioavailability, and protects fetuses against therapeutic agents. A recent clinical study showed that inhibition of BCRP significantly increases the oral bioavailability of topotecan in cancer patients from 40 % to 97 % (Kruijtzer et al., 2002) . Thus, BCRP is important in determining absorption, distribution, and elimination of drugs that are substrates for this transporter.
Many of the drugs transported by BCRP (listed above) are also substrates of P-gp. Some have suggested that the substrate selectivity of BCRP substantially overlaps with that of P-gp (Litman et al., 2000; Doyle and Ross, 2003) . Therefore, to comprehensively evaluate the importance of BCRP in the in vivo disposition of drugs, it is important to determine the substrate profile of BCRP. Hence, we have asked if the HIV protease inhibitors (HPIs), excellent substrates of P-gp, are substrates of BCRP. In this paper, we present data that addresses this question. This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on March 8, 2004 as DOI: 10.1124 at ASPET Journals on April 29, 2016 jpet.aspetjournals.org Downloaded from 7 treated with trypsin-EDTA prior to harvesting for subculturing or efflux assays. Only cells within six passages were used in subsequent transport experiments.
Whole cell lysates were prepared as follows: Briefly, cell pellet from 5 x 10 6 cells was suspended in approximately 100 µ l of lysis buffer containing 50 mM Tris/HCl, pH 7.5, 10 mM MgCl 2 , 50 µ g/ml PMSF, 0.25% (w/v) SDS, 250 µ g/ml DNase I (Invitrogen), and protease inhibitors (Complete TM , Roche Molecular Biochemicals). The mixture was then incubated on ice for 1 h with gentle vortexing occasionally and centrifuged at 2,400 x g for 10 min at 4 o C. The supernatant was subjected to immunoblotting as described below. Protein concentrations were determined using a modified Lowry assay (Peterson, 1979) and bovine serum albumin as standard.
SDS-Polyacrylamide Gel Electrophoresis and Immunoblotting.
Gel electrophoresis of whole cell lysates from various cell lines was carried out using 10% SDS-polyacrylamide mini gels in a Bio-Rad Mini-protein II electrophoresis cell. Standard western blot procedure was followed.
Briefly, proteins were transferred on Immuno-P nitrocellulose membranes (Millipore, Billerica, MA) using 25 mM Tris, 192 mM glycine and 20% methanol buffer. The blot was blocked with 5% skim milk in TBS-T buffer (10 mM Tris/HCl, pH 7.5, 0.15 mM NaCl, 0.05% Tween-20) for 1 h at room temperature. The blot was incubated with mAb BXP-21 (which recognizes an internal epitope in the nucleotide-binding domain (aa 271-396) of BCRP (Maliepaard et al., 2001) ) (Kamiya Biomedical Co., Seattle, WA) at 1:500 dilution as the primary antibody for 2 h at room temperature followed by washing the blot 3 times with TBS-T. The blot was then incubated with the secondary antibody, goat anti-mouse (GAM)-HRP conjugate (dilution 1:10,000) (BioRad, Hercules, CA) for 1 h at room temperature. The blot was then washed 3 and MRP2, the same procedure as described above was used except that the primary antibody used was mAb F4 (Kamiya) for P-gp (dilution 1:1,000), mAb QCRL-1 (Signet, Dedham, MA)
for MRP1 (dilution 1:500) and mAb M 2 III-6 (Alexis Biochemicals) for MRP2 (dilution 1:100).
Flow Cytometric Efflux Assays. The efflux assays were essentially the same as previously described Robey et al., 2001a) washed once with ice-cold PBS and re-suspended in 0.5 ml of incubation buffer (with or without FTC) and incubation was continued for 1 h at 37°C to allow maximum efflux of the drug. The efflux reactions were stopped by washing the cells once with ice-cold PBS. Cell pellet was dissolved in one ml of 1% SDS and 900 µl of the lysate was subjected to counting in a scintillation counter. Counts were normalized to protein concentration that was measured by the modified Lowry assay using the remaining lysate. The intracellular levels of HPIs were calculated based on radioactivity associated with the cell pellet and expressed as pmoles of drug/µg protein or fmoles of drug/µg protein. We tried various drug loading and efflux times and found that the experiments produced the optimal efflux activity with 30 min drug loading and 1 h efflux.
Data Analysis. IC 50 values representing the inhibitory effectiveness of HPIs on BCRP-mediated MX efflux in the flow cytometric efflux assays were calculated by fitting the following model to 
Results

Expression of BCRP in HEK cells. Whole cell lysates prepared from various HEK cell lines
stably expressing wild-type BCRP (482R) and its two mutants (482T and 482G) were subjected to immunoblotting for analysis of BCRP expression. Fig.1 shows substantial expression of BCRP in the HEK cells after 30 seconds exposure. 482R and 482G displayed comparable levels of expression. However, 482T was expressed in amounts approximately 20% lower than 482R and 482G. Similar expression pattern of BCRP in HEK cells has been reported earlier . Since HPIs are known substrates for P-gp, MRP1 or MRP2, to rule out any possible contribution of these transporters, the same protein samples were subjected to immunoblotting for P-gp, MRP1 and MRP2. No P-gp, MRP1 or MRP2 was detected in the samples after a brief exposure for 1 min. Faint bands for these transporters appeared only upon prolonged exposure of the blot for approximately 2 h. The levels of expression of P-gp, MRP1 and MRP2 were comparable in both the BCRP-expressing and vector-control cells (data not shown). These bands represent the endogenous expression levels of these transporters. Thus, relative to the expression of BCRP, the HEK cells express little of endogenous P-gp, MRP1 or MRP2. the BCRP expressing cells could be abrogated by addition of 10 µ M FTC, a specific BCRP inhibitor ( Fig. 2A ). This suggests that the decrease in intracellular MX is mediated by BCRP.
Effects of
Therefore, the change in MX fluorescence (∆F) upon addition of BCRP inhibitors can be used to express inhibition of BCRP activity as described in "Materials and Methods". In preliminary studies, we found that 10 µ M MX in the presence and absence of 10 µ M FTC produced ∆ F values that were optimal for determining BCRP activity ( Fig. 2A ). Hence, concentrations of 10 µ M MX and 10 µ M FTC were used in all the subsequent flow cytometric efflux assays.
We first examined whether HPIs are BCRP inhibitors. concentrations was observed (Fig. 3) . This decrease was likely due to the cytotoxic effect of the HPIs on the cells exposed at higher concentrations. Interestingly, the reduction was more pronounced for 482R cells than cells expressing the two mutants. This is consistent with the observation that 482R appears to be more sensitive to inhibition by the HPIs than the mutants 482T and 482G. 
Inhibition of [ 3 H]-MX
Discussion
HPIs, including saquinavir, indinavir and ritonavir, are high affinity substrates for P-gp which limits their oral absorption and entry into the CNS (Kim et al., 1998a; Kim et al., 1998b; Lee et al., 1998; Polli et al., 1999) . Recent studies (Huisman et al., 2002; Williams et al., 2002) have shown that MRP2 also effectively transports saquinavir, ritonavir and indinavir. Thus, low and/or variable oral bioavailability of HPIs could be explained in part by the high level expression of P-gp and MRP2 in the small intestine and the liver, where these transporters reduce absorption and increase intestinal and hepatobiliary clearance of drugs. BCRP shares many similarities with P-gp and MRP2 with respect to substrate specificity and tissue localization. Like P-gp and MRP2, BCRP is highly expressed in the luminal membranes in the small intestine and liver (Maliepaard et al., 2001; Doyle and Ross, 2003) . In fact, BCRP transcript has been reported to be expressed in greater amount than P-gp in the intestine (Taipalensuu et al., 2001) . Moreover, BCRP is also highly expressed in sites of clinical importance for HIV drug action such as the blood-brain barrier and placental barrier (Maliepaard et al., 2001; Cooray et al., 2002) . Thus, BCRP would be expected to alter pharmacokinetic properties of HPIs if these drugs are BCRP substrates. This prompted us to investigate whether the HPIs are substrates and/or inhibitors of BCRP. The results of our study provide the first direct evidence that ritonavir, saquinavir and nelfinavir are effective inhibitors of BCRP but indinavir and amprenavir are not, and that none of the HPIs is a substrate for BCRP.
Two different analyses suggest that ritonavir, saquinavir and nelfinavir inhibit BCRP.
Ritonavir, saquinavir and nelfinavir effectively increased intracellular MX fluorescence in the BCRP-expressing cells in a concentration-dependent manner as would be expected for BCRP inhibitors (Fig. 2 and Fig. 3 ). Indinavir and amprenavir did not significantly change intracellular cells, whereas indinavir and amprenavir did not (Fig. 4) . Given the fact that the five HPIs tested in this paper have extremely diverse chemical structures and molecular sizes (their molecular weights range from 506 to 767), it remains to be investigated why some of the HPIs interact with BCRP but others do not and what determines the binding affinity of these compounds to the transporter.
We also found that the wild-type BCRP (482R) was significantly more sensitive than its mutants 482T and 482G to inhibition by the HPIs, suggesting that position 482 in BCRP may be a critical determinant for binding of the HPIs to BCRP (Table 1) . Position 482 has been shown to be critical in determining substrate specificity of BCRP (Honjo et al., 2001; Allen et al., 2002; Volk et al., 2002; Chen et al., 2003; Robey et al., 2003) . Thus, our data again support the evidence that mutations at position 482 in BCRP have a significant effect on ligand recognition by the transporter.
To determine if HPIs are substrates of BCRP, we measured their efflux in cells expressing the wild-type BCRP. The efflux of radiolabeled ritonavir, saquinavir, nelfinavir and amprenavir was not significantly different in the vector control and BCRP-overexpressing cells, suggesting that these drugs are not transported by BCRP (Fig. 5) . These data are consistent with the results previously reported by other laboratories. Wang et al. (2003) Taken together, our results and the data published by others indicate that the HPIs tested in this paper are not substrates of BCRP. The data presented here are the first report where the inhibitory characteristics of HPIs to BCRP have been characterized in detail. Moreover, this is the first time that transport of HPIs by human BCRP has been measured directly. We noticed that the efflux of radiolabeled ritonavir and saquinavir by both the vector control HEK cells and the 482R cells could be inhibited by incubation with FTC, suggesting that there is an endogenous efflux transporter for ritonavir and saquinavir in the HEK cells that can be inhibited by FTC.
Several HPIs investigated in this study are substrates of P-gp, MRP1 or MRP2 (Lee et al., 1998; Williams et al., 2002) ; however, it is unlikely that any of these pumps is the endogenous transporter for ritonavir and saquinavir in the HEK cells, based on the following evidence: first, we have shown that the HEKs cells express little of endogenous P-gp, MRP1 or MRP2; and second, there is no evidence thus far to suggest that FTC is able to inhibit these transporters.
Recently, Imai et al. (2003) also reported the existence of an endogenous transporter for MX in LLC-PK1 cells that can be inhibited by FTC. Whether the endogenous transporter found by Imai et al. (2003) and the one reported in this study are the same transporter is unknown.
The molecular mechanism by which HPIs inhibit BCRP transport is unknown. However, the finding that a molecule that binds to and inhibits a drug transporter but itself is not transported is not unexpected. Zhang et al. (2000) found that saquinavir inhibits transport of tetraethylammonium by the human organic cation transporter OCT1, but itself is not transported by OCT1. Similarly, the nucleoside analogue chloroadenosine was reported to inhibit transport of nucleoside substrates by the human intestinal hCNT2 and hCNT1 Na + -nucleoside transporters, but itself is not a substrate of these transporters (Lum et al., 2000; Patil et al., 2000) . Most recently, Nakanishi et al. (2003a) studied reciprocal inhibition of BCRP transport by its substrates including daunorubicin, mitoxantrone and flavopiridol and found that, in any pair of two substrates, none of the substrate caused mutual inhibition of the transport of the other. For example, flavopiridol significantly inhibited BCRP (482T)-mediated transport of daunorubicin, but daunorubicin did not reciprocally inhibit BCRP (482T) transport of flavopiridol. This led them to propose that BCRP may contain multiple ligand interaction sites. Thus, it is possible that MX and the HPIs have distinct or overlapping binding sites on BCRP.
The finding that ritonavir, saquinavir and nelfinavir are effective inhibitors but not substrates of BCRP is clinically significant with respect to drug-drug interactions with HPIs.
Although all the HPIs are potent inhibitors of CYP3A enzymes and their inhibitory effectiveness to these enzymes is similar, they produce profoundly different degrees of clinically significant drug interactions (Unadkat and Wang, 2000) . One possible explanation of these differences is the possibility that the HPIs inhibit multiple and different transporters in the intestine and liver with different potencies. As BCRP is highly expressed in the intestine, one such transporter could be BCRP. The current recommended doses of ritonavir, saquinavir and nelfinavir for monotherapy are, respectively, 600 mg twice daily, 600 mg three times daily, and 750 mg three times daily. 
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